| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
NCE Biomedical Co.,Ltd. |
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
4-(Diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine manufacturers
- HQL-79
-
- $188.00
-
2026-04-21
- CAS:162641-16-9
- Purity:
- Supply Ability: 10g
|
| | 4-(Diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine Basic information |
| Product Name: | 4-(Diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine | | Synonyms: | 4-(Diphenylmethoxy)-1-(3-2H-tetrazol-5-yl)propyl]-piperidine;HQL-97;CS-620;HQL 79;HQL79;Piperidine, 4-(diphenylmethoxy)-1-[3-(2H-tetrazol-5-yl)propyl]-;1-(3-(1H-Tetrazol-5-yl)propyl)-4-(benzhydryloxy)piperidine;4-benzhydryloxy-1-[3-(2H-tetrazol-5-yl)propyl]piperidine;HQL-79 | | CAS: | 162641-16-9 | | MF: | C22H27N5O | | MW: | 377.48 | | EINECS: | | | Product Categories: | | | Mol File: | 162641-16-9.mol | ![4-(Diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine Structure](CAS/GIF/162641-16-9.gif) |
| | 4-(Diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine Chemical Properties |
| Boiling point | 553.6±60.0 °C(Predicted) | | density | 1.21 | | storage temp. | Store at RT | | solubility | DMSO: soluble2mg/mL, clear (warmed) | | form | powder | | pka | 4.85±0.10(Predicted) | | color | white to beige | | InChI | 1S/C22H27N5O/c1-3-8-18(9-4-1)22(19-10-5-2-6-11-19)28-20-13-16-27(17-14-20)15-7-12-21-23-25-26-24-21/h1-6,8-11,20,22H,7,12-17H2,(H,23,24,25,26) | | InChIKey | TZQGXAHOROZEKN-UHFFFAOYSA-N | | SMILES | [nH]1nnnc1CCCN2CCC(CC2)OC(c4ccccc4)c3ccccc3 |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | 4-(Diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine Usage And Synthesis |
| Uses | HQL-79 is a selective PGE synthase inhibitor. | | Biological Activity | HQL 79 is an orally active anti-allergic agent th at acts as an antagonist for histamine H1 receptors (H1R), eliciting anti-asthmatic effects. It interacts with prostaglandin (PG) D synthase (H-PGDS) in the catalytic region. It may be potential lead due to its H-PGDS inhibition to tre at allergies.', 'HQL-79 is a selective inhibtor of hematopoietic prostaglandin D (PGD) synthase, one of two synthases involved in the production of Prostaglandin D2 (PGD2) from arachidonic acid. PGD2 is a lipid signaling molecule, which activates two receptors, DP1 involved in centrally mediated processes such as sleep and pain and DP2 involved and inflammation. The two PGD synthases involved in its synthesis are lipocalin-type (L-PGDS) and hematopoietic (H-PDGS), which acts to form PGD2 in mast cells, Th2 cells, microglia, and other inflammatory cells/tissues. HQL-79 selectively inhibited the activity of recombinant H-PGDS with an IC50 of 6 μM and had almost no effect on COX-1, COX-2, m-PGES, or L-PGDS up to 300 μM. HQL-79 has anti-inflammatory activity in vitro and in vivo. | | storage | Store at RT |
| | 4-(Diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine Preparation Products And Raw materials |
|